Dr. Gahl and his team at the National Human Genome Research Institute are seeking volunteers aged 18 and older with primary FSGS to participate in a research study on the effects of an experimental drug, ManNAc, on this disease. The study aims to assess the long-term safety and tolerability of ManNAc and determine whether it can reduce protein in the urine of people with FSGS.
The study includes a physical exam, medical and family history review, urine tests, and blood draws. Participants will need to make two inpatient visits to the NIH (each lasting 2-3 overnights) and five outpatient NIH visits (lasting a few hours each). ManNAc, an experimental sugar-based drug, is taken orally as a powder dissolved in water twice daily. The NIH will cover the costs of lodging, travel, and meals.
CONTACT US
NIH Clinical Center
Office of Patient Recruitment
866-411-1222 (TTY users dial 7-1-1)
ccopr@nih.gov
Follow us on Instagram @nih_ccopr
NIH research study #002066-HG
The NIH Clinical Center, America’s Research Hospital is located in Bethesda, MD, Metro red line (Medical Center stop)
